Experimental Ebola Treatments Bypassing Usual Regulatory Hurdles

Experimental Ebola treatments are moving with lightning speed through a regulatory process that, for most drugs, can take years.  The urgency of the lethal epidemic in three West African countries - Guinea, Liberia and Sierra Leone - means a number of promising treatments are bypassing the usual hurdles toward approval.  Before a new drug gets the green light from U.S. regulators, researchers are required to conduct in-depth clinical trials on people to demonstrate the...

© La Voix de l'Amérique - mercredi 15 octobre 2014